UNIVERSITY OF LEICESTER, UNIVERSITY OF LOUGHBOROUGH & UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST JOINT RESEARCH & DEVELOPMENT SUPPORT OFFICE

Similar documents
Specialist Research Ethics Guidance Paper RESEARCH INVOLVING ADULT PARTICIPANTS WHO LACK THE CAPACITY TO CONSENT

Consent to research. A draft for consultation

MENTAL CAPACITY ACT POLICY (England & Wales)

Deciding whether a person has the capacity to make a decision the Mental Capacity Act 2005

Assessment of Mental Capacity and Best Interest Decisions

!This booklet is for family and friends of anyone who.!these decisions may be related to treatment they re

the general hospital: case discussions

4. Adults Lacking Capacity to Consent to Research

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

Unit 5 MCA & DOLS. Deprivation of Liberty Safeguards (DOLS) Lasting Powers of Attorneys (LPAs) Advance Decisions to Refuse Treatment (ADRTs)

RESEARCH INVOLVING ADULTS WHO LACK CAPACITY: HOW HAVE RESEARCH ETHICS COMMITTEES INTERPRETED THE REQUIREMENTS?

THE MENTAL CAPACITY ACT FACT SHEET FOR SOCIAL SCIENTISTS

ECT and the law. Dr Hugh Series. Consultant old age psychiatrist, Oxford Health NHS FT Member, Law Faculty, University of Oxford

Research involving adults lacking the capacity to consent: The Mental Capacity Act 2005

PROCEDURE Mental Capacity Act. Number: E 0503 Date Published: 20 January 2016

STANDARD OPERATING PROCEDURE

What happens if I cannot make decisions about my care and treatment?

Advance Statements. What is an Advance Statement? Information Line: Website: compassionindying.org.uk

Seeking Consent: Working with People in Prison

STANDARD OPERATING PROCEDURE SOP 720 RISK ASSESSMENT OF TRIALS SPONSORED. BY THE NNUH and UEA

Mental Capacity Implementation Programme. Mental Capacity Act 2005

Janet Grace Consultant Psychiatrist Kerry Graham Acting MH Legislation Development Lead. Rajesh Nadkarni Acting Executive Medical Director

Division of Research Policy

Standard Operating Procedures (SOP) Research and Development Office

International Standard for Athlete Evaluation. July 2015

Informed Consent Procedures and Writing Informed Consent Forms

Planning for a time when you cannot make decisions for yourself

1. INTRODUCTION 2. HOARDING PROCEDURE

ASSESSMENT OF DECISION MAKING CAPACITY IN ADULTS PARTICIPATING IN A RESEARCH STUDY 6/8/2011

Annual Progress and Safety Reporting SOP for HEY-sponsored CTIMPs

Oregon Health & Science University Office of Research Integrity Guidance on Human Subjects Research with Decisionally Impaired Adults

SOP-QA-30 V Scope

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ZOLEDRONIC ACID. Patient s first names.

Good Practice Guidance on Covert Administration of Medication

Restraint and the Mental Capacity Act 2005 in operational policing Mental Health & Policing Briefing Sheet 4

Standard Operating Procedure Research Governance

MENTAL HEALTH. Power of Attorney

Classification Rules and Regulations

Mental Capacity Act 2005 Competency Toolkit

Legal. Advance Directives. About this factsheet. Factsheet Leg 8 October of 12

STANDARD OPERATING PROCEDURE

DIRECTIONS FOR USING THE MENTAL HEALTH ADVANCE DIRECTIVE POWER OF ATTORNEY FORM

Protecting Vulnerable Groups Guidance for Care Inspectorate staff and service providers Publication date: October 2012

CENTRES 8 th International Clinical Ethics Conference Mental Health - Challenges in Clinical Ethics

Day care and childminding: Guidance to the National Standards

Amendments to the Mental Health Act 1986 (Vic) regarding involuntary treatment and Community Treatment Orders

INFORMED CONSENT PROCEDURES & WRITING PARTICIPANT INFORMATION AND CONSENT FORMS FOR RESEARCH

IPC Athletics Classification Rules and Regulations

Planning for the Future: A Guide for Individuals and Families

STANDARD OPERATING PROCEDURE

Research Community Forum

TREATMENT OF INVOLUNTARY PATIENTS 2.4

SERVICE SPECIFICATION 6 Conservative Management & End of Life Care

South Staffordshire and Shropshire Healthcare NHS Foundation Trust

PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FERRERI / IELSG PROTOCOL. Patient s first names. Date of birth

Approval for research carried out on human extracted teeth from Birmingham School of Dentistry Tooth Bank under ethical approval no: 14/EM/2811

Enhanced Service Specification. Childhood seasonal influenza vaccination programme 2018/19

MENTAL HEALTH ADVANCE DIRECTIVE

Enhanced Service Specification. Childhood seasonal influenza vaccination programme 2017/18

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CYTARABINE (HIGH DOSE)

Pandemic influenza. Guidance on the delivery of and contract arrangements for primary care dentistry

A mental health power of attorney allows you to designate someone else, called an agent, to

The challenges faced by people with a stoma and dementia

Informed Consent and Assessment of Capacity to Consent to Research Policy

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ABVD. Patient s first names.

Chief Dental Officer England: Advice on commercial practice of online registered dental practitioners selling patient group directions for NHS

Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM BEVACIZUMAB. Patient s first names. Date of birth.

IPC Athletics. Classification Rules and Regulations

making a referral for breast imaging Standard Operating Procedure

Translation and Interpretation Policy

Needlestick injuries and blood-borne viruses: decisions about testing adults who lack the capacity to consent

Patient identifier/label: Page 1 of 7 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM EC-T: EPIRUBICIN / CYCLOPHOSPHAMIDE - DOCETAXEL

Factsheet 72 Advance decisions, advance statements and living wills

Standard Operating Procedure CPFT/SOP003 Serious Breach of Protocol or GCP in CTIMPs

Shropshire Multi-Agency Mental Capacity Act Guidance September 2015 Page 1

Introduction 4. Important information about consent to legal parenthood 7. Women s consent to treatment and storage form (IVF and ICSI) (WT form) 9

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CISPLATIN + ETOPOSIDE ORAL/INTRAVENOUS

COMPETENT AUTHORITY (UK) MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES

ARBD Assessment, Diagnosis and MCA

The Mental Capacity Act 2006 and the management of challenging behaviours: Applications to the Northern Ireland Capacity Bill

INSTRUCTIONS FOR COMPLETING THE CLINICAL TEAM REPORT FOR GUARDIANSHIP AND/OR CONSERVATORSHIP

Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CABOZANTINIB. Patient s first names.

Scottish Parliament Region: North East Scotland. Case : Tayside NHS Board. Summary of Investigation

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

Competence, consent and Coercion: A medico-legal conundrum. Dr Rees Tapsell Ms Meenal Duggal

Paediatric Assessments

Who Decides? Understanding the Mental Capacity Act 2005 CDC Conference January 2017 Daisy Russell

Consistency in REC Review

Enhanced service specification Childhood seasonal influenza vaccination programme NHS England gateway reference: 01641

DoLS Code of Practice para 4.33 The purpose of the mental health assessment is to establish whether the relevant person is suffering from a mental dis

World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects

Ethical Conduct for Research Involving Humans

GOOD PRACTICE GUIDE. Consent to Treatment: A guide for mental health practitioners

EPF s response to the European Commission s public consultation on the "Summary of Clinical Trial Results for Laypersons"

FREQUENTLY ASKED QUESTIONS ABOUT MENTAL HEALTH ADVANCE DIRECTIVES GUIDE FOR CONSUMERS

Classification Rules and Regulations

Mental Health Act 2007: Workshop. Section 12(2) Approved Doctors. Participant Pack

COT/ BAOT Briefings List

Research & Development. J H Pacynko and J Illingworth. Research, pharmacy and R&D staff

SCDHSC0368 Present individuals preferences and needs

Transcription:

UNIVERSITY OF LEICESTER, UNIVERSITY OF LOUGHBOROUGH & UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST JOINT RESEARCH & DEVELOPMENT SUPPORT OFFICE STANDARD OPERATING PROCEDURES University of Leicester (UoL) Research Governance Office SOP S-1034 UoL Version 3, November 2016 Inclusion of Incapacitated Adults in Research Studies Sponsored by the University of Leicester OFFICE BASE Research Governance Office Research & Enterprise Division University of Leicester Fielding Johnson Building University Road Leicester LE1 7RH Effective Date: April 2017

Standard Operating Procedure: SOP S-1034 UoL Inclusion of Incapacitated Adults in Research Studies Sponsored by the University of Leicester Research Governance Office November 2016 1. INTRODUCTION This Standard Operating Procedure (SOP) defines the process required when including adults that lack capacity either temporarily or permanently, in Clinical Trials of Investigational Medicinal Products (CTIMPs) sponsored by the University of Leicester (UoL). The EU Clinical Trial Directive 2001/20/EC sets out fundamental principles relating to the inclusion of adults lacking capacity to give informed consent in clinical trials and these were transposed into UK law via the Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031). Persons who are incapable of giving legal consent to clinical trials should be given special protection and such persons may not be included in clinical trials if the same results can be obtained using persons capable of giving informed consent. Investigational medicinal products may be administered to adults lacking capacity (such as persons with dementia or psychiatric patients) only when there are grounds for assuming that the direct benefit to the subject outweighs the risk. The details of how consent will be obtained and how subjects lacking capacity will be enrolled must be clearly stated in the protocol and Integrated Research Application System (IRAS) documentation. The study must have been reviewed and given a Favourable Opinion by an appropriate NHS Research Ethics Committee (REC) and HRA in accordance with their SOPs. 2. SCOPE This SOP applies to all CTIMPs sponsored by UoL which include adults lacking capacity, either temporarily or permanently, in their target patient population. 3. DEFINITIONS 3.1 Adult Lacking Capacity An adult lacking capacity is an adult unable by virtue of physical or mental incapacity to give informed consent. An adult refers to a person aged 16 or over. Regulations do not define capacity or incapacity to give consent and investigators and other team members involved in enrolment of study subjects are responsible for assessing decision-making capacity-see Section 6. 3.2 Personal Legal Representative A person not connected with the conduct of the trial who is: suitable to act as the legal representative by virtue of their relationship with the adult; and available and willing to do so. The personal representative does not have to be the next of kin and there is no hierarchy in which relatives or friends need to be approached. Responsibility lies with the investigating team to identify a suitable person after consulting the subject s usual care staff and health records. A Personal Legal Representative could include someone with a lasting power of attorney under the Mental Capacity Act 2005 in respect of welfare decisions. Professional and paid carers are excluded. SOP S-1034 UoL Inclusion of Incapacitated Adults in Research Studies Sponsored by the University of Leicester Page 2 of 6

3.3 Professional Legal Representative A person not connected with the conduct of the study who is: the doctor primarily responsible for the adult s medical treatment; or a person nominated by the healthcare provider/host organisation. In all cases the legal representative must not be a person connected with the conduct of the trial defined as: the Sponsor of the study; a person employed or engaged by, or acting under arrangements with, the Sponsor and who undertakes activities connected with the management of the trial; an investigator for the study; a health care professional who is a member of an investigator s team for the purposes of the trial; or a person who provides health care under the direction or control of a person referred to above, whether in the course of the trial or otherwise. 4. CONDITIONS AND PRINCIPLES All the conditions and principles listed in Part 5 of Schedule 1 to SI 2004/1031, The Medicines for Human Use (Clinical Trials) Regulations 2004 must normally be satisfied if an incapacitated adult is to be included in a clinical trial. These are listed in Appendix 1. The conditions require that adults lacking capacity receive information according to their capacity of understanding about the trial and its risks and benefits. Where subjects are capable of assessing information and forming an opinion, any explicit wish to refuse participation in the trial or be withdrawn at any time must be considered by the investigator. This also means that in addition to the legal consent required, it will be appropriate in some cases to explore whether the subject assents or does not object to participating in the trial. 5. NOMINATION OF PROFESSIONAL LEGAL REPRESENTATIVES PRIOR TO START OF A STUDY The requirement for a study to have Professional Legal Representative will be discussed during the Sponsor Risk assessment process and a suitable individual must have been identified prior to the start of recruitment. The UoL Research Governance Manager or delegate is responsible for the oversight of the nomination process for individuals to act in the capacity of Professional Legal Representatives and the process must be documented using the Professional Legal Representative Nomination Form (Appendix 2). It is the responsibility of the Sponsor to provide indemnity for Professional Legal Representatives. 6. RESPONSIBILITIES DURING THE CONDUCT OF A CLINICAL TRIAL A Personal Legal Representative should be sought initially to give consent and only if a suitable personal representative is not available or willing to give consent should a Professional Legal Representative be approached. SOP S-1034 UoL Inclusion of Incapacitated Adults in Research Studies Sponsored by the University of Leicester Page 3 of 6

The Chief Investigator /Principal Investigator or approved delegate must ensure that all legal representatives receive sufficient verbal and written information such that they are able to make an informed decision on behalf of the subject. They must also ensure that the Professional Legal Representative has read and understood this SOP. If consent has been given by a Professional Legal Representative and subsequently a Personal Legal Representative becomes available this person should be approached to see whether they are willing to consent on behalf of the subject and asked to do so if they are. Similarly if a subject regains capacity when consent has been given by a legal representative the subject s consent must be sought. 7. DECISION MAKING CAPACITY AND THE MENTAL CAPACITY ACT The provisions for approving research under the Mental Capacity Act do not apply to CTIMPs but the remainder of the Act does apply insofar as it is relevant to the conduct of a CTIMP. Investigators should be aware in particular of the following: a person must be assumed to have capacity unless it is established that he lacks capacity, and is not to be treated as unable to make a decision unless all practicable steps to help him do so have been taken without success; a person is considered to lack capacity where he is unable to make a decision for himself in relation to a particular matter at the material time (that is when a particular decision needs to be made), due to an impairment of or disturbance in the functioning of the mind or brain. The impairment or disturbance could be temporary or permanent; a person is unable to make a decision for himself if he is unable to understand the information relevant to the decision, retain the information, use or weigh up the information in making the decision, or communicate his decision (by any means). 8. EMERGENCY SITUATIONS Where, as part of a study, the treatment needs to be administered urgently to an adult lacking capacity, time may not allow for written consent to be obtained first from a legal representative. Adults lacking capacity are allowed to be entered into a study prior to informed consent being obtained, provided that, and having taken into account the nature and particular circumstances of the case: it is necessary to take action for the purpose of the study as a matter of urgency; but it is not reasonably practicable to obtain consent prior to entering the subject; and the action to be taken is in accordance with a procedure approved by the REC. Where an incapacitated adult is recruited in an emergency situation without prior informed consent, steps must be taken to seek informed consent either from the subject (if capacity has been recovered) or from a legal representative as soon as possible after the initial emergency has passed. Where consent is withheld, the subject must be withdrawn from the study; samples and data collected up to this point may be retained with the consent of the subject or legal representative. SOP S-1034 UoL Inclusion of Incapacitated Adults in Research Studies Sponsored by the University of Leicester Page 4 of 6

9. LOSS OF CAPACITY DURING A STUDY If a capable adult gives informed consent to take part in a study, but subsequently becomes unable to give informed consent by virtue of physical or mental incapacity, the consent previously given when capable remains legally valid. If a capable adult refuses informed consent, and subsequently becomes unable to give informed consent, the refusal is legally binding. The individual cannot be entered into the study by seeking consent from a legal representative. More information and guidance on clinical trials involving adults lacking capacity is available in an online toolkit on the HRA website. 10. RESPONSIBILITIES Responsibility Undertaken by Activity 1 CI CI or delegate Ensure that exact details of how consent will be obtained or how subjects lacking capacity will be enrolled is clearly stated in the protocol and IRAS application. 2 CI CI or delegate Ensure that the Personal or Professional Legal Representative receives both verbal and written study specific information to ensure they have adequate information to make an informed decision on behalf of the subject. 3 Research Governance Manager Research Governance Manager or Delegate Ensure oversight of the nomination process for individuals to act in the capacity of Professional Legal Representatives. 4 CI CI or delegate Ensure that the process of nomination of an individual as a Professional Legal Representative has been completed and authorised by the Research Governance Office prior to any named Professional Legal Representative being asked to give consent on behalf of an incapacitated subject. 5 CI CI or approved delegate 6 All staff involved in CTIMPs recruiting Incapacitate d Adults All staff involved in CTIMPs recruiting Incapacitated Adults Ensure that this SOP is adhered to in that the most appropriate consent is in place in a timely manner for each subject recruited to the study. Ensure they are aware of the policies and guidelines relevant to entry of incapacitated subjects in clinical trials. Ensure that the interests of the subject always prevail over those of science and society. SOP S-1034 UoL Inclusion of Incapacitated Adults in Research Studies Sponsored by the University of Leicester Page 5 of 6

This table is used to track the development and approval of the document and any changes made on revised / reviewed versions: Author / Lead Officer: Reviewed by: DEVELOPMENT AND APPROVAL RECORD FOR THIS DOCUMENT Joanne Thompson UoL Research Sponsorship Management and Operations Group. Job Title: Medical Writer, Clear Clinical Research Ltd Approved by: Professor Nigel Brunskill Date Approved: Date June 2015 Nov 2016 REVIEW RECORD Issue Reviewed By Description Of Changes (If Any) No. 1 Wendy Gamble Updated to include changes of name in joint office and appendix numbering. 2 Diane Delahooke Change of logo and RGO address. Addition of HRA. DISTRIBUTION RECORD: Date Name Dept Received SOP S-1034 UoL Inclusion of Incapacitated Adults in Research Studies Sponsored by the University of Leicester Page 6 of 6